Obesity, type 2 diabetes and related metabolic disorders are associated with reduced mitochondrial function in skeletal muscle and other organs (1) . However, causality of aberrant mitochondrial activity in the etiology of these diseases and the exact mechanisms linking metabolic pathologies to mitochondrial dysfunction are still under debate. Therefore, a better molecular understanding of this observation is required in order to design novel therapeutic strategies aimed at modulation of mitochondrial function in these disease contexts. The silent mating type information regulation 2 homolog 1 (SIRT1) and the peroxisome proliferator-activated receptor γ co-activators 1 (PGC-1) are important regulators of mitochondrial function in skeletal muscle (1) . In response to deacetylation by SIRT1, PGC-1α is activated and subsequently promotes an oxidative muscle fiber phenotype. In turn, activity and mitochondrial oxidative function (7; 8) . In most tissues, PARP-1 accounts for the vast majority (>85%) of cellular PARP activity, and is therefore also the major NAD + consumer (6) . Thus, PARP-1 deletion presumably affects SIRT1 primarily due to increased NAD + levels (8) . In contrast, even though PARP-2 null mice also show increased NAD + levels (7), PARP-2 also acts as a transcriptional repressor of SIRT1 (7).
Modulation of PARP activity provides a novel therapeutic strategy to increase SIRT1 expression and activity in skeletal muscle, and represents an alternative to pharmacological activation of SIRT1 using resveratrol or SRT1720 (9; 10). Interestingly, several studies indicate that PARP activity in murine skeletal muscle is dysregulated during high fat diet (HFD) feeding (8) was therefore postulated as a major mechanism leading to mitochondrial dysfunction in these mice.
Although simple and attractive, the findings do not exclude the idea that PARPs, apart from acting as a transcriptional repressor of SIRT1 (7), also interact with other transcriptional regulators such as forkhead box O1 (FoxO1) (12) and peroxisome proliferator-activated receptor γ (PPARγ) (13) . Further, direct PARylation of mitochondrial proteins has also been demonstrated to reduce oxidative function (14) , suggesting that the connection between PARP-2 and mitochondrial dysfunction in skeletal muscle is multifaceted. In a series of elegant experiments, the authors of the new report investigated the long elusive mechanism behind increased PARP-2 expression in HFD-fed mice by performing a miRNA screen in skeletal muscle. Several differentially regulated miRNAs were discovered, of which two (miR-149 and miR712-3p) were significantly down-regulated with HFD feeding and therefore considered potential candidates for the observed regulation of PARP-2. However, only miR-149 was able to reduce PARP-2 levels in vitro, and it bound to a conserved seed region in the 3'UTR of PARP-2.
In a well-designed in vitro setup, the authors could then demonstrate that overexpression of miR-149 in cultured myotubes led to a reduction in PARP-2, elevated NAD + levels, increased SIRT1 activity, and concomitantly promoted mitochondrial biogenesis. These in vitro data are in many aspects opposite to the muscle phenotype observed in HFD fed mice, and it will therefore be interesting to see whether overexpression of miR-149 in skeletal muscle in vivo will have a protective effect against obesity-induced metabolic dysfunction. Skeletal muscle-specific inhibition of PARP-2 activity would also circumvent the dichotomy present in global PARP-2 null mice, which simultaneously exhibit increased peripheral insulin sensitivity as well as β-cell dysfunction and insulinopenia (7).
Furthermore, it will be important to elucidate whether the miR-149/PARP-2/SIRT1-axis postulated here in a mouse model is also dysregulated in human obesity, and thus a valid therapeutic target in patients.
Mohamed and colleagues have identified a novel miRNA that modulates oxidative function in skeletal muscle by affecting the intracellular levels of the metabolite NAD + . Besides miR-149, other miRNAs such as miR-494 (15), miR-23 (16) and miR-696 (17) analogously affect mitochondrial biogenesis and function in skeletal muscle, however by inhibiting different targets (Fig. 1) .
Interestingly, all of these miRNAs are regulated by exercise (15) (16) (17) . Since both exercise and caloric restriction are linked to increased SIRT1 activity and improved mitochondrial function, it will be interesting to investigate whether miR-149 and in extension also PARP-2 are differentially regulated in these metabolically beneficial states. In conclusion, this study provides novel evidence of dysregulated PARP-2 during obesity, and proposes an important role of miR-149 in the control of intracellular NAD + levels, thus providing another example of a miRNA that acts as a major regulator of cellular metabolism. The relevance of this paper is underscored by the emerging role of PARPs in metabolic regulation (6) , and thus provides a framework for futures studies on the connection between PARP activity and mitochondrial function. Moreover, these findings put an emphasis on the clinical relevance of PARP-inhibitors, not only in the field of oncology (18), but also as an incipient therapeutic strategy for treatment of obesity, and obesity-related metabolic disorders. This dichotomy in the regulation of cellular metabolism in muscle can furthermore be modulated by pharmacological interventions aimed at PARP-2 and SIRT1 activities as well as elevation of cellular NAD+ levels using PJ34, resveratrol (RSV), SRT1720, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), respectively.
